Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Myeloma
  • Chronic Lymphocytic Leukemia
  • Gynecologic Cancers
  • Genomic Testing
  • Melanoma
  • Genitourinary Cancers
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Dr. Jose P. Zevallos on Tobacco-Related Mutations in HPV-Positive Oropharyngeal SCC

March 3, 2016
By Jose P. Zevallos, MD, MPH, FACS
Video

Zevallos says the study consisted of 66 patients and found that there were distinct genomic differences between HPV-positive smokers and non-smokers.

Jose P. Zevallos, MD, MPH, FACS, assistant professor, director of Oncologic Research, University of North Carolina School of Medicine, discusses a recent study that looked at molecular profiles determined by targeted DNA sequencing of patients with HPV-positive oropharyngeal squamous cell carcinoma (SCC). The purpose of the study was to determine if patients with HPV-positive oropharyngeal SCC, who were also smokers, had a different mutational status than non-smokers.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content

Unveiling the Unseen: The Future of Posttreatment Cancer Detection

Unveiling the Unseen: The Future of Posttreatment Cancer Detection

Sabrina Serani
June 17th 2025
Article

Advancements in cancer care focus on precise detection of measurable residual disease, enhancing monitoring and relapse prediction through innovative technologies and AI integration.

Read More


Deepening Our Understanding of CAR T Manufacturing: A Novel Profiling Platform

Deepening Our Understanding of CAR T Manufacturing: A Novel Profiling Platform

Sabrina Serani
June 16th 2025
Article

A new platform comprehensively profiles CAR T-cells during manufacturing, revealing phenotypic shifts. This allows for shorter timelines, better outcomes, and personalized therapies.

Read More


Taletrectinib: A New Advance in ROS1-Mutant NSCLC

Taletrectinib: A New Advance in ROS1-Mutant NSCLC

Sabrina Serani
June 13th 2025
Article

Taletrectinib emerges as a groundbreaking treatment for ROS1-mutant NSCLC, offering hope with its CNS activity and lower neurological side effects.

Read More


Cytoreductive Nephrectomy in the Era of Immunotherapy for Kidney Cancer

Cytoreductive Nephrectomy in the Era of Immunotherapy for Kidney Cancer

Jordyn Sava
June 12th 2025
Article

Hyung Kim, MD, discussed the PROBE trial, a trial in progress, for patients with advanced kidney cancer.

Read More


Participants Discuss Optimal Immunotherapy Choices for Metastatic NPC

Participants Discuss Optimal Immunotherapy Choices for Metastatic NPC

Targeted Oncology Staff
June 11th 2025
Article

During a live event, Deborah Wong, MD, PhD, discussed the role of PD-1 inhibitors in nasopharyngeal cancer and their accessibility/safety.

Read More


Adagrasib Plus Pembro Shows Promising First-Line Activity in KRAS G12C-Mutant NSCLC

Adagrasib Plus Pembro Shows Promising First-Line Activity in KRAS G12C-Mutant NSCLC

Jordyn Sava
June 11th 2025
Article

Read More

Related Content

Unveiling the Unseen: The Future of Posttreatment Cancer Detection

Unveiling the Unseen: The Future of Posttreatment Cancer Detection

Sabrina Serani
June 17th 2025
Article

Advancements in cancer care focus on precise detection of measurable residual disease, enhancing monitoring and relapse prediction through innovative technologies and AI integration.

Read More


Deepening Our Understanding of CAR T Manufacturing: A Novel Profiling Platform

Deepening Our Understanding of CAR T Manufacturing: A Novel Profiling Platform

Sabrina Serani
June 16th 2025
Article

A new platform comprehensively profiles CAR T-cells during manufacturing, revealing phenotypic shifts. This allows for shorter timelines, better outcomes, and personalized therapies.

Read More


Taletrectinib: A New Advance in ROS1-Mutant NSCLC

Taletrectinib: A New Advance in ROS1-Mutant NSCLC

Sabrina Serani
June 13th 2025
Article

Taletrectinib emerges as a groundbreaking treatment for ROS1-mutant NSCLC, offering hope with its CNS activity and lower neurological side effects.

Read More


Cytoreductive Nephrectomy in the Era of Immunotherapy for Kidney Cancer

Cytoreductive Nephrectomy in the Era of Immunotherapy for Kidney Cancer

Jordyn Sava
June 12th 2025
Article

Hyung Kim, MD, discussed the PROBE trial, a trial in progress, for patients with advanced kidney cancer.

Read More


Participants Discuss Optimal Immunotherapy Choices for Metastatic NPC

Participants Discuss Optimal Immunotherapy Choices for Metastatic NPC

Targeted Oncology Staff
June 11th 2025
Article

During a live event, Deborah Wong, MD, PhD, discussed the role of PD-1 inhibitors in nasopharyngeal cancer and their accessibility/safety.

Read More


Adagrasib Plus Pembro Shows Promising First-Line Activity in KRAS G12C-Mutant NSCLC

Adagrasib Plus Pembro Shows Promising First-Line Activity in KRAS G12C-Mutant NSCLC

Jordyn Sava
June 11th 2025
Article

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.